We are thrilled to announce a $1 Million investment from the California Institute for Regenerative Medicine (CIRM) for Defined's clinical-grade PSC maintenance medium for enabling stem cell therapy manufacturing.
The goal of CIRM’s Translational program is to support promising stem cell-based or gene projects that accelerate completion of translational stage activities necessary for advancement to clinical study or broad end use. Those can include therapeutic candidates, diagnostic methods or devices and novel tools that address critical bottlenecks in research.
This significant grant from CIRM will further support Defined Bioscience's mission to enable safer, more efficient, and scalable stem cell manufacturing processes. HiDef-B8 growth media for stem cells has been growing in popularity in many research areas and soon we will be able to support projects transitioning into clinical applications and scale.
#stemcells #HiDefB8 #Definedbioscience #DefinedBio #CIRM #ipsc